Recombinant Human Lactate Dehydrogenase B/LDHB Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9205-HB

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9205-HB-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P07195

Conjugate

Unconjugated

Applications

Enzyme Activity

View all Lactate Dehydrogenase B/LDHB Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human Lactate Dehydrogenase B/LDHB protein
Ala2-Leu334, with N-terminal Met and 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

37 kDa

SDS-PAGE

36 kDa, reducing conditions

Activity

Measured by its ability to reduce pyruvate to lactate.
The specific activity is >60,000 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

9205-HB
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Lactate Dehydrogenase B/LDHB

A hallmark of most cancer cells is an altered metabolism involving a shift to aerobic glycolysis with lactate production coupled with a higher uptake of glucose as the main source of energy. Lactate dehydrogenase (LDH) is key to this shift by catalyzing the formation of lactate by reducing pyruvate with NADH, which also generates NAD(+) that is essential for the continuity of glycolysis (1). Inhibiting LDH activity has an anti-proliferative effect on cancer cells (2). It may reverse the resistance of tumor cells to conventional chemo- and radiotherapy. Recent research has renewed interest in LDH as an anticancer drug target (3). LDH enzymes have three homologous subunits LDHA, LDHB and LDHC. The combination of these three results to multiple isozymes, including LDH-M and LDH-H. Mutations in LDHB cause lactate dehydrogenase B deficiency, a condition with no deleterious effects on health (4).

References

  1. Faloppi L. et al. (2016) Sci Rep. 6:24136.
  2. Ghosh, M. et al. (2016) Chem. Commun. 52:2401.
  3. Augoff, K. et al. (2015) Cancer Lett. 358:1.
  4. Maekawa M. et al. (1993). Hum. Genet. 91:423.
  5. Maekawa M. et al. (1990). Biochem. Biophys. Res. Commun. 168:677.

Alternate Names

Epididymis Secretory Protein Li 281, HEL-S-281, LDH-H, LDHB, LDHBD, Renal Carcinoma Antigen NY-REN-46, TRG-5

Entrez Gene IDs

3945 (Human); 16832 (Mouse); 24534 (Rat)

Gene Symbol

LDHB

UniProt

P07195

Additional Lactate Dehydrogenase B/LDHB Products

Product Documents for Recombinant Human Lactate Dehydrogenase B/LDHB Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Lactate Dehydrogenase B/LDHB Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.